His primary areas of study are Internal medicine, Immunology, Lupus erythematosus, Systemic lupus erythematosus and Surgery. Internal medicine is represented through his Rheumatology, Connective tissue disease, Systemic disease, Cohort study and Immunopathology research. The study incorporates disciplines such as Systemic lupus, Disease and Clinical significance in addition to Rheumatology.
His Lupus erythematosus research is multidisciplinary, incorporating perspectives in Randomized controlled trial, Intention-to-treat analysis, Family medicine, Physical therapy and Severity of illness. David A. Isenberg focuses mostly in the field of Systemic lupus erythematosus, narrowing it down to topics relating to Anti-SSA/Ro autoantibodies and, in certain cases, Anti-nuclear antibody. The concepts of his Surgery study are interwoven with issues in Lupus nephritis and Adverse effect.
David A. Isenberg mainly investigates Immunology, Internal medicine, Lupus erythematosus, Systemic lupus erythematosus and Antibody. His research on Immunology frequently links to adjacent areas such as Disease. His work deals with themes such as Gastroenterology and Surgery, which intersect with Internal medicine.
As part of the same scientific family, David A. Isenberg usually focuses on Lupus erythematosus, concentrating on Connective tissue disease and intersecting with Systemic disease and Immunopathology. His Systemic lupus erythematosus study incorporates themes from Clinical trial and Discoid lupus erythematosus. He has researched Antibody in several fields, including Molecular biology and Antigen.
David A. Isenberg mainly focuses on Internal medicine, Systemic lupus erythematosus, Disease, Cohort and Rituximab. The various areas that David A. Isenberg examines in his Internal medicine study include Gastroenterology and Lupus erythematosus. His Lupus erythematosus research incorporates elements of Young adult and Severity of illness.
His Systemic lupus erythematosus research is multidisciplinary, incorporating elements of Body mass index and Arthritis. His research integrates issues of Dermatology, Belimumab and Intensive care medicine in his study of Rituximab. His Antibody study is focused on Immunology in general.
David A. Isenberg spends much of his time researching Internal medicine, Rituximab, Rheumatology, Systemic lupus erythematosus and Cohort. David A. Isenberg applies his multidisciplinary studies on Internal medicine and In patient in his research. His Rheumatology study also includes
His studies in Systemic lupus erythematosus integrate themes in fields like Cancer research, Tyrosine kinase, Bruton's tyrosine kinase, Immune system and B cell. His Belimumab research is under the purview of Immunology. His research in Immunology is mostly concerned with Avidity.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.
Michelle Petri;Ana Maria Orbai;Graciela S. Alarcõn;Caroline Gordon.
Arthritis & Rheumatism (2012)
Systemic lupus erythematosus.
Anisur Rahman;David A Isenberg.
The New England Journal of Medicine (2008)
The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus.
Dafna Gladman;Ellen Ginzler;Charles Goldsmith;Paul Fortin.
Arthritis & Rheumatism (1996)
Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community.
Claudio Vitali;Stefano Bombardieri;Haralampos M. Moutsopoulos;Genesio Balestrieri.
Arthritis & Rheumatism (1993)
Compromised Function of Regulatory T Cells in Rheumatoid Arthritis and Reversal by Anti-TNFα Therapy
Michael R. Ehrenstein;Jamie G. Evans;Animesh Singh;Samantha Moore.
Journal of Experimental Medicine (2004)
CD19+CD24hiCD38hi B Cells Exhibit Regulatory Capacity in Healthy Individuals but Are Functionally Impaired in Systemic Lupus Erythematosus Patients
Paul A. Blair;Lina Yassin Noreña;Fabian Flores-Borja;David J. Rawlings.
Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus: The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial
Joan T. Merrill;C. Michael Neuwelt;Daniel J. Wallace;Joseph C. Shanahan.
Arthritis & Rheumatism (2010)
The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes
Matthew H. Liang;Michael Corzillius;Sang Cheol Bae;Robert A. Lew.
Arthritis & Rheumatism (1999)
Systemic Lupus Erythematosus
Inam Haq;David A Isenberg.
Mortality in systemic lupus erythematosus.
S. Bernatsky;J. F. Boivin;L. Joseph;S. Manzi.
Arthritis & Rheumatism (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: